neuro-oncology
(5)
Jason Levin Stayed With the Bet Long Enough for the Science to Change
For more than a decade, the Orbus co-founder helped carry one drug through financing, patents and a 343-patient trial. Then a new tumor classification changed the question - and the company’s next chapter.
Orbus Bet $71 Million on One Brain-Cancer Trial - Then the Definition of the Disease Changed
A tiny Palo Alto biotech took an old molecule into a global Phase 3 trial. The broad result failed, but a new molecular map of brain cancer revealed where the drug may actually work - and offered a playbook for anyone building in a market whose definitions move mid-experiment.
GT Medical Technologies, Inc.
GT Medical Technologies is a Tempe, Arizona medical device company that developed GammaTile, an FDA-cleared bioresorbable radiation therapy implant for operable brain tumors. Founded by brain tumor specialists from the Barrow Neurological Institute, the company places collagen tiles embedded with Cesium-131 seeds directly into the tumor cavity at the time of surgery, delivering immediate, targeted radiation while sparing healthy tissue. Backed by a $100M Series E led by Viking Global Investors, GT Medical has treated more than 2,000 patients and is pursuing randomized trials to establish GammaTile as a standard of care.
Per Langoe
Per Langoe is the CEO of GT Medical Technologies, the Tempe, Arizona company behind GammaTile, an FDA-cleared radiation therapy tile that gets sewn into the brain the same moment a tumor is removed. He arrived in February 2024 after co-founding and selling Palette Life Sciences to Teleflex for $600 million, bringing more than two decades in radiation oncology commercialization from Pharmacia, Q-Med, Galderma and Nestle Skin Health.
Ben Woodington
Ben Woodington is the co-founder and CEO of Coherence Neuro, a deep-tech company building SOMA-1, a button-sized, MRI-safe brain-computer interface that listens to and electrically modulates brain tumors from the inside. A Cambridge-trained chemist-turned-engineer who once built smart inhalers and minimally invasive spinal-cord interfaces, Woodington pivoted his neurotechnology to oncology after realizing almost no one was applying neural-interface engineering to cancer. He argues electricity should become the fourth pillar of cancer therapy alongside surgery, drugs, and radiation, and raised a $10M seed in late 2025 to take the work toward first human trials.